

300.1003

#18A
m.m.
8/13/03

For fee only

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Sharmila S. Gollamudi Art Unit: 1616
Re: Application of: Chih-Ming CHEN, et al.
Serial No.: 09/435,576
Filed: November 8, 1999
For: HMG-COA REDUCTASE INHIBITOR
EXTENDED RELEASE FORMULATION

AMENDMENT UNDER 37 CFR §1.111 and
STATEMENT OF SUBSTANCE OF INTERVIEW UNDER 37 CFR §1.133

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

July 22, 2003

I. INTRODUCTORY COMMENTS

Sir:

In response to the Office Action mailed April 4, 2003, please amend the above-referenced application as provided in the section below entitled "AMENDMENT TO THE CLAIMS." The "REMARKS" section of the present amendment includes the substance of the interview as required under 37 CFR §1.133.

Received from <212 736 2427> at 7/22/03 2:59:29 PM (M. Daylight Time)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)		Docket Number (Optional)
In re Application of Chih-Ming CHEN		300.1003
Application Number 09/435,576	Filed November 8, 1999	
For HMG-COA REDUCTASE INHIBITOR EXTENDED RELEASE FORMULATION		
Group Art Unit 1616	Examiner S. Gollamudi	

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a response in the above identified application.

The requested extension and appropriate non-small-entity fee are as follows (check time period desired):

<input checked="" type="checkbox"/> One month (37 CFR 1.17(a)(1))	\$110.00
<input type="checkbox"/> Two months (37 CFR 1.17(a)(2))	\$
<input type="checkbox"/> Three months (37 CFR 1.17(a)(3))	\$
<input type="checkbox"/> Four months (37 CFR 1.17(a)(4))	\$
<input type="checkbox"/> Five months (37 CFR 1.17(a)(5))	\$

☐ Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown above is reduced by one-half, and the resulting fee is: \$

☐ A check in the amount of the fee is enclosed.

☐ Payment by credit card. Form PTO-2038 is attached.

☐ The Commissioner has already been authorized to charge fees in this application to a Deposit Account.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 60-0552.

I have enclosed a duplicate copy of this sheet.

I am the ☐ applicant/inventor.

☐ assignee of record of the entire interest. See 37 CFR 3.71

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

☒ attorney or agent of record.

☐ attorney or agent under 37 CFR 1.34(a).

Registration number if acting under 37 CFR 1.34(a):

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Signature
Clifford M. Davidson
Typed or printed name

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ Total of forms are submitted.

#18
M.M.
8/13/03

7/14/2003 HHAY22 0000004 500552 JULY 22 2003
FC:1251 110.00 DA Date

Burden Hour Statement: This form is estimated to take 0.1 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JUL 22 2003 1:57PM DOK